Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott David Solomon, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr P. Ponikowski, Marc Steven Sabatine, Inder S. Anand, Jan Bělohlávek, Michael Böhm, Chern‐En Chiang, Vijay Chopra, Rudolf A. de Boer, Akshay Suvas Desai, Mirta Díez, Jarosław Dróżdż, Andrej Dukát, Junbo Ge, Jonathan G. Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta E. A. Ljungman, Béla Péter Merkely, José Carlos Nicolau, Eileen O’Meara, Mark Colquhoun Petrie, Pham Nguyễn Vinh, Morten Schou, Sergey N. Tereshchenko, Subodh Verma, Claes Held, David L. DeMets, Kieran F. Docherty, Pardeep S. Jhund, Olof Bengtsson, Mikaela Sjöstrand, Anna-Maria Langkilde
New England Journal of Medicine · 2019 · 7,529 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C., Chopra, V., Boer, R. A. de, Desai, A. S., Díez, M., Dróżdż, J., Dukát, A., Ge, J., … Langkilde, A.-M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/nejmoa1911303
In text: (McMurray et al., 2019)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. METHODS: In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. RESULTS: Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).
Related papers
- Harmonizing the Metabolic Syndrome2009
- 2013 ACCF/AHA Guideline for the Management of Heart Failure2013
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging2015
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure1991
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.1978
Metadata from OpenAlex (CC0). Citations are generated from the published record.